All In MedTech

Device Trial Radar · NCT05609656

Electroporation and Immunotherapy in Metastatic Colorectal Cancer

Calcium Electroporation in Combination With Irreversible Electroporation and Immunotherapy in Patients With Proficient Mismatch Repair System (pMMR) Metastatic Colorectal Cancer - A Prospective, Phase 2 Study

Last checked: Nov 19, 2026Latest source record: Jun 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Jan 26, 2023

Primary completion

Apr 8, 2024

Study completion May 2, 2024

Sponsor

Lead sponsor
Ismail GögenurAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 8, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium electroporation (CaEP) performed concurrently with irreversible electroporation (IRE) followed by a PD-1 inhibitor (pembrolizumab).

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • Irreversible electroporationDevice

    Percutaneous ablation of a metastatic lesion. Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is CE approved for medical use.

  • Calcium electroporationDevice

    Just before the reversible electroporation, calcium chloride will be injected into the primary tumor. The electroporation will be delivered as at least four pulses and up to eight pulses. The device is repositioned after each pulse to ensure coverage of the entire surface area of the tumor. The reversible electroporation regime will be delivered through the endoscopic device EndoVE®, while the ePORE® will be used for pulse generation, both CE approved.

  • PembrolizumabDrug

    Pembrolizumab 200 mg as an IV infusion every 3 weeks (+/- 3 days) for up to 12 months Pembrolizumab is an immune checkpoint inhibitor (PD-1-inhibitor).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence rate of adverse events according to CTCAE v. 4.0Time frame: up to 1 month after end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zealand University Hospital

    Køge, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.